FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease

29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...

Read more →

U.S. drug prices sky high in international comparison

22 July 2022 - U.S. residents are paying more than twice as much for prescription drugs as people living in other ...

Read more →

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

25 July 2022 - First and only biologic recommended for EU approval in patients with severe asthma with no phenotype ...

Read more →

Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

25 July 2022 - First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities ...

Read more →

Enhertu granted priority review in the U.S. for patients with HER2 low metastatic breast cancer

25 July 2022 - Application being evaluated under FDA Real-Time Oncology Review and Project Orbis. ...

Read more →

Applications for proposed first of a kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

25 July 2022 - Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple ...

Read more →

FDA describes plans to expand remote regulatory assessments

22 July 2022 - The US FDA released draft guidance on Friday that formalises its plans for using remote regulatory assessments ...

Read more →

Importing medicines from overseas: guidance needed

25 July 2022 - If a doctor is aware that an expensive medicine their patient desperately needs is available from a ...

Read more →

Aurinia announces positive CHMP opinion for Lupkynis (voclosporin) for the treatment of adults with active lupus nephritis in Europe

22 July 2022 - Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA  efficacy study ...

Read more →

Rhythm Pharmaceuticals receives positive CHMP opinion for Imcivree (setmelanotide) for the treatment of obesity and control of hunger in patients with Bardet-Biedl syndrome

European Commission decision anticipated in fourth quarter of 2022. ...

Read more →

Calls for PHARMAC to fund more effective shingles vaccine with cases expected to rise due to COVID-19

24 July 2022 - There are calls from medical experts for PHARMAC to fund a more effective vaccine for shingles, ...

Read more →

New campaign to promote COVID-19 oral antiviral treatments

22 July 2022 - The Australian Government today launched a new advertising campaign to encourage eligible Australians to access life-saving COVID-19 ...

Read more →

CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

22 July 2022 - The CHMP recommendation is based on results across four Phase 3 studies: TENAYA and LUCERNE in neovascular age-related ...

Read more →

CHMP adopts positive opinion recommending Veklury (remdesivir) receive full marketing authorisation for the treatment of patients with COVID-19

22 July 2022 - If Granted by the European Commission, Veklury will become the only direct-acting antiviral with full marketing authorisation ...

Read more →

EMA CHMP recommends use of the Moderna COVID-19 booster in adolescents (12-17 Years) in the European Union

22 July 2022 -  Moderna today announced that the EMA's CHMP has adopted a positive opinion recommending a variation to ...

Read more →

European Union regulation of health technology assessment: what is required for it to succeed?

22 July 2022 - After considerable discussion and debate, the European Commission proposal for the regulation of health technology assessment was ...

Read more →